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The hemagglutinins (HAs) of human H1 and H3 influenza viruses and avian H5 influenza virus were
produced as recombinant fusion proteins with the human immunoglobulin Fc domain. Recombinant
HA-human immunoglobulin Fc domain (HA-HuFc) proteins were secreted from baculovirus-infected
insect cells as glycosylated oligomer HAs of the anticipated molecular mass, agglutinated red blood cells,
were purified on protein A, and were used to immunize mice in the absence of adjuvant. Immunogenicity
was demonstrated for all subtypes, with the serum samples demonstrating subtype-specific hemaggluti-
nation inhibition, epitope specificity similar to that seen with virus infection, and neutralization. HuFc-
tagged HAs are potential candidates for gene-to-vaccine approaches to influenza vaccination.
The need for a rapid and scalable vaccine response to
emerging influenza virus strains is widely recognized (31).
Traditional vaccines are largely based on whole virus, where
the isolation of suitable seed strains, the supply of sufficient
fertilized hen’s eggs or cell culture, and the requirement for
a robust immune response in the most at-risk populations all
impinge on the productivity and speed of response that can
be achieved (17, 29). Direct expression of the major vaccine
antigen, the virion surface hemagglutinin (HA) protein, in
insect cells can improve the speed and flexibility of thera-
peutic responses (6), but the immunogenicity of the product
is often low, necessitating large doses of vaccine to generate
a level of seroconversion consistent with protection (8, 15,
30). Oligomeric rather than monomeric HA was shown re-
cently to be an improved immunogen (35), but oligomeriza-
tion was ensured through the addition of an extraneous
sequence of unknown risk for human immunization. Im-
proving the immunogenicity of the HA with an immune-
silent tag could be compatible with vaccine design if it could
be shown that it would not compromise HA performance
and would be consistent with rapid and high-level expres-
sion. Glycoproteins tagged with the human immunoglobulin
Fc domain (HuFc) have been shown to have enhanced im-
munogenicity as a result of an increased half-life (26, 39) or
Fc receptor-mediated uptake by antigen-presenting cells
such as dendritic cells (5, 21, 23) or both. We have investi-
gated the potential of HA-HuFc fusion proteins as influenza
vaccine candidates and addressed whether (i) HuFc tagging
was demonstrable for several HA subtypes, (ii) the resulting
fusion proteins were immunogenic in the absence of addi-
tional adjuvant, (iii) the serum response was neutralizing,
and (iv) the serum response was typical of that obtained
following influenza immunization.
A unified cloning strategy was adopted for all the HA
subtypes selected for expression. Baculovirus transfer vec-
tors contained a well-cleaved signal peptide derived from
the baculovirus gp64 major surface glycoprotein and the
human Fc domain flanking directional genomic restriction
sites for high-throughout baculovirus expression as de-
scribed elsewhere (22, 38). Other studies have shown this
expression strategy to be robust and widely applicable (2, 3,
5, 20). The HA sequences used were derived from influenza
viruses A/New York/221/03 (a prepandemic seasonal human
H1 subtype), A/Panama/2007/99 (a widely used human H3
subtype), and A/Vietnam/1194/04 (the widely distributed
and occasionally zoonotic avian H5 subtype). The sequence
representing the mature external domain of each HA was
amplified from available clones or synthesized de novo from
the deposited database sequence. Following the construc-
tion of the transfer vectors, recombinant baculoviruses were
produced as described previously (40), and the expression
and secretion of HuFc-tagged HA were confirmed by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blot analysis of cells and super-
natant at 2 days postinfection (Fig. 1A). HA-HuFC fusion
protein present in the supernatant was concentrated by lec-
tin (lens culnaris) chromatography and purified by chroma-
tography on immobilized protein A. Yields were typically 2
to 5 mg/liter (109 cells), and the product was essentially
pure (Fig. 1B). Gel filtration chromatography and velocity
gradient analysis revealed oligomeric structures ranging
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from dimers to hexamers (Fig. 1C). There was negligible
aggregate apparent in the void volume or at the bottom of
the gradients (Fig. 1C, fraction 9), and the product was
endotoxin free (7). Purified HA-HuFc fusion protein (10 g
per dose) was used to immunize mice (n  3) subcutane-
ously at 2-week intervals in the absence of adjuvant (for
three inoculations in all), and the serum samples were col-
lected after a further 2 weeks. Serotype-specific responses,
assayed using nontagged HA, were observed for H1 and H3
subtypes by both enzyme-linked immunosorbent assay
(ELISA) and Western blot analysis, but the H5 sera, while
reacting most strongly to the cognate antigen, also bound
well to the H1 HA (Fig. 2A). Cross-reaction between H5
antibodies and H1 HA, including neutralizing antibodies,
has been previously described elsewhere (12) and is proba-
bly related to the structures of the H5 and H1 HA1 domains
being closely related (27). Interestingly, cross-reaction was
not reciprocal (Fig. 2A), plausibly as a result of glycan
shielding of H5 (34). All three HA subtypes were immuno-
genic, with no evidence of the poor immunogenicity attrib-
uted to attenuated H5 vaccines (17, 34). A dose-ranging
study showed significant seroconversion (down to 100 ng per
dose) with the same immunization regimen, a human equiv-
alent dose of 24 g as calculated by body surface area (24),
lower than that observed for nontagged HA (30). Hemag-
glutination inhibition (HAI) assays performed with guinea
pig or turkey red blood cells, which contain a mixture of
2,6- and 2,3-linked sialic acids, gave titers of 1/200 and
1/100 for the H3 and H5 sera, respectively. The H1 protein
agglutinated poorly, and 50% HAI was unobtainable. Cross-
subtype HAI was not observed. Isotyping showed the re-
sponses to be predominantly composed of IgG1, with some
IgG2a and IgG2b (Fig. 2B), and a Th2 response with some
Th1 contribution, which is consistent with a result reported
previously for soluble oligomeric HA (4, 35). We found only
kappa light-chain use. To assess whether the polyvalent se-
rum responses to soluble HA-HuFc immunogens were fo-
cused on the receptor binding domain of HA as seen in
experimental infection studies (10), we immunized mice
with further H5-Fc fusion proteins bearing mutations L133V
plus A138V or Q196R plus S227N (Fig. 3A). These muta-
tions alter receptor specificity and affinity in synthetic gly-
can-based assays (1, 36, 37) and can be likened to those of
influenza strains with altered SA affinities and preferences
that arise following virus passage in the presence of an
antibody response generated in response to the parental HA
FIG. 1. Expression and characterization of HA-HuFc fusion proteins. (A) Baculovirus-expressed HA-HuFc was present in cell extracts (track
1) and in supernatant (track 2) and following purification (track 3). (B) Western blot analysis performed with an anti-Hu Ig conjugate showed
intermediates present in cell extracts but no evidence of breakdown in the supernatant or following purification. (Tracks are as described for panel
A.) (C) Velocity gradient analysis of purified HA-HuFc showed a distribution of solution molecular masses estimated to range from dimers (200
kDa) to hexamers (600 kDa). No aggregate was present in the heavier fractions. Numbers to the left in panels A and C represent molecular mass
markers, with values in kilodaltons. The numbers at the top of panel C represent solution molecular mass makers taken from a parallel gradient
analysis, with values in kilodaltons. Panels A and C show stained 10% SDS-PAGE gels, and panel B shows chemiluminescence. Data shown are
representative of the H3 subtype and are typical of other HA subtypes.
FIG. 2. Serum responses to HA-HuFc fusion proteins. (A) Sera from mice immunized with H1, H3, and H5 HA-HuFc proteins were used
at a 1:1,000 dilution for Western blot analysis of H1, H3, and H5 HA proteins lacking the Fc tag after separation by 10% SDS-PAGE. Track
C, control insect cell extract; track 1, H1 HA; track 3, H3 HA; track 5, H5 HA. Numbers to the left of the panel represent molecular mass
markers, with values in kilodaltons. (B) Isotyping of the serum responses to each immunogen. Gray bar, H1; bar with diagonal stripes, H3;
clear bar, H5.
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(10, 16). The overall immunogenicity of the sera obtained
from each immunization was not significantly affected by the
introduced amino acid changes, as shown by the ELISA
titers determined with HA-HuFc (Fig. 3B). However, when
the normalized sera were subjected to titration using wild-
type H5 HA lacking the Fc tag, the sera generated with the
H5 HAs containing either L133V plus A138V or Q196R
plus S227N demonstrated significantly reduced titers com-
pared to the sera generated with the wild-type H5 HA (Fig.
3C). The predominant antibody response to HA-HuFc fu-
sion proteins is therefore to the HA1 domain and, in par-
ticular, to the receptor binding site whose conformation is
altered by the introduced mutations. To further confirm that
the epitope specificity of the polyvalent response to soluble
HA-HuFc fusion protein resided in the HA1 domain, the
serum samples generated with wild-type H5-HuFc were as-
sayed for linear epitope recognition with a set of overlap-
ping peptides (20-mers overlapping by 10 residues) made
with the A/Vietnam/1194/04 HA sequence. Reactivity was
limited to discrete peptides located at the top of the HA1
domain (Fig. 4A), which broadly correlated with the epitope
map for the H5 HA of A/Vietnam/1203/04, as determined by
investigation of virus escape mutants (13), or the HA of
A/Hong Kong/482/97, as determined by an antigen display
library approach (18). The neutralizing activity of each se-
rum sample was assessed by an entry inhibition assay using
luciferase-encoding lentivirus vectors pseudotyped by H5
HA (28). Neutralization induced by the sera generated with
the wild-type H5 sequence had an endpoint titer of 320,
whereas neither of the serum samples generated with the
mutant HAs had appreciable activity, although the serum
samples generated with H5 Q196R plus S227N had marginal
activity at the highest dose (Fig. 4B). Thus, fusion of HA at
the C terminus to HuFc allows rapid purification of a con-
formationally relevant molecule that is immunogenic with-
out the presence of added adjuvant and induces serum re-
sponses to the HA1 domain that are neutralizing, at least for
the H5 HA studied here.
A number of recombinant routes to influenza vaccination
have demonstrated proof of principle (6, 11, 14). Unmodi-
fied recombinant HA may require high doses to ensure a
protective response, limiting the opportunity for antigen
sparing during periods of high demand, while the more
immunogenic candidates, such as virus-like particles (VLP),
are complex immunogens that have associated issues with
respect to manufacturing yield. Our data suggest that a
simple tagged recombinant form of HA can serve as an
effective immunogen; equivalent constructs for H7, H9, and
swine virus H1 have been found also to be equally immu-
nogenic (not shown). Immunization with oligomeric HA was
shown recently to provide protective immunity (35), but that
study used a tag of uncertain clinical acceptance. HuFc-
FIG. 3. Expression, purification, and immunization of H5-HuFc-based receptor binding site mutants. (A) Wild-type (WT) H5 or H5 bearing
two site-directed changes as shown was expressed and purified as described in the text. Mutant yields and stability were unaltered compared to
parental H5 results. The results determined by 10% SDS-PAGE analysis of the stained final purified materials are shown. Numbers to the left of
the panel represent molecular mass markers (track M), with values in kilodaltons. (B) Titration of polyvalent sera by ELISA using H5-Fc.
(C) Titration of polyvalent sera by ELISA using wild-type H5 lacking the Fc tag after normalization of the titer as described for panel A. In both
panels, the serum sample results are depicted as follows: }, H5 wild type; f, H5 L133V plus A138V; Œ, H5 Q196R plus S227N; and E, normal
mouse serum. The assay was done in duplicate, and the averages of the results are plotted. Duplicate data points in the assays did not differ by
more than 5%.
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tagged therapeutic vaccines are in current clinical use (19),
and their use is growing (25). Thus, HA-HuFc could be
clinically acceptable, particularly for members of groups
such as the elderly, who respond poorly to current vaccines
(9). HuFc-mediated presentation of HA sequences capable
of generating cross-protective responses (32, 33) would be
particularly interesting.
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